Intensive diabetes management for high-risk patients: How best to deliver?

Diabetes Care

Volumn 32, Issue 6, 2009, Pages 1132-1133

  Marshall, Sally M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; EDITORIAL; HEALTH CARE DELIVERY; HIGH RISK PATIENT; HUMAN; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CARDIOVASCULAR DISEASES; DELIVERY OF HEALTH CARE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; HUMANS; KIDNEY FAILURE, CHRONIC; LOSARTAN;

EID: 66549128458     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-0540     Document Type: Editorial

References (17)

1. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno 2 randomised study. Lancet 1999;353:617-622 (Pubitemid 29087981)
2. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393 (Pubitemid 36159355)
3. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591
4. Chan JC, So W-Y, Yeung C-Y, Ko GT, Lau I-T, Tsang M-W, Lau K-P, Siu S-C, Li JK, Yeung VT, Leung WY, Tong PC, the SURE Study Group. Effects of Structured Versus Usual Care on Renal Endpoint in Type 2 Diabetes: the SURE study: a randomized multicenter translation study. Diabetes Care 2009;32:977-982
5. Chan JCN, Wat NMS, So WY, Lam KSL, Chua CT, Wong TS, Morad Z, Dickson TZ, Hille D, Zhang Z, Cooper ME, Shahinfar S, Brenner BM, Kurokawa K. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: an Asian perspective from the RENAAL study. Diabetes Care 2004;27:874-879 (Pubitemid 38420207)
6. Leung WYS, So WY, Tong PCY, Chan NN, Chan JCN. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. Am J Med 2005;118:1414-1421 (Pubitemid 41832339)
7. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS75). Diabetologia 2006;49:1761-1769 (Pubitemid 44025030)
8. Kong AP, Yang X, Ko GT, So WY, Chan WB, Ma RC, Ng VW, Chow CC, Cockram CS, Tong PC, Wong V, Chan JC. Effects of treatment targets on subsequent cardiovascular events in Chinese patients with type 2 diabetes. Diabetes Care 2007;30:953-959 (Pubitemid 46556592)
9. Khunti K, Gadsby R, Millett C, Majeed A, Davies M. Quality of diabetes care in the UK: comparison of published quality-of-care reports with results of the Quality and Outcomes Framework for Diabetes. Diabet Med 2007;24:1436-1441 (Pubitemid 350179431)
10. Wu JY, Leung WY, Chang S, Lee B, Zee B, Tong PC, Chan JC. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. Br Med J 2006;333:522-526 (Pubitemid 44408460)
11. Franklin VL, Waller A, Pagliari C, Greene SA. A randomised controller trial of Sweet Talk, a text-messaging system to support young people with diabetes. Diabet Med 2006;23:1332-1338 (Pubitemid 44787797)
12. Deakin TA, Cade JE, Williams R, Greenwood DC. Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med 2006;23:944-954 (Pubitemid 44257938)
13. Jonsson B, CODE-2 Advisory Board. Revealing the cost of type II diabetes in Europe. Diabetologia 2002;45 (Suppl.):S5-S12
14. Williams R, Van Gall L, Lucioni C, CODE-2 Advisory Board. Assessing the impact of complications on the costs of type II diabetes. Diabetologia 2002;45 (Suppl.):S13-S17
15. American Diabetes Association. Economic costs of diabetes in the U.S in 2007. Diabetes Care 2008;31:596-615
16. Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy 2008;6:103-112
17. Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008;31:1510-1515